WO2021057998A1 - 一种吡咯并氨基哒嗪酮化合物的制备方法 - Google Patents

一种吡咯并氨基哒嗪酮化合物的制备方法 Download PDF

Info

Publication number
WO2021057998A1
WO2021057998A1 PCT/CN2020/118309 CN2020118309W WO2021057998A1 WO 2021057998 A1 WO2021057998 A1 WO 2021057998A1 CN 2020118309 W CN2020118309 W CN 2020118309W WO 2021057998 A1 WO2021057998 A1 WO 2021057998A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
compound represented
formula
preparation
Prior art date
Application number
PCT/CN2020/118309
Other languages
English (en)
French (fr)
Inventor
管忠俊
祝令建
黄建
Original Assignee
上海森辉医药有限公司
上海盛迪医药有限公司
江苏恒瑞医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海森辉医药有限公司, 上海盛迪医药有限公司, 江苏恒瑞医药股份有限公司 filed Critical 上海森辉医药有限公司
Publication of WO2021057998A1 publication Critical patent/WO2021057998A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present disclosure belongs to the field of medicine, and relates to a preparation method of a pyrroloaminopyridazinone compound.
  • Immune cells can generally be divided into two types: T cells and B cells.
  • the main function of B cells is to secrete various antibodies to help the body resist various foreign invasions.
  • Bruton tyrosine protein kinase (BTK) is a member of the tyrosine protein kinase subfamily and belongs to the Tec family of kinases. It is mainly expressed in B cells and distributed in the lymphatic system, hematopoietic and blood system.
  • BCR B cell receptor
  • CLL chronic lymphocytic leukemia
  • NHL non-Hodgkin lymphoma
  • MCL mantle cell lymphoma
  • DLBCL diffuse large B cell lymphoma
  • B cells have played a role in the pathogenesis of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and other immune diseases. It is clinically proven.
  • Bruton's tyrosine protein kinase (BTK) is a key protein kinase in the BCR signaling pathway. It can regulate the maturation and differentiation of normal B cells, and is also closely related to a variety of B cell lymphoid tissue disorders. Therefore, the targeted small molecule inhibitor BTK can provide benefits for the treatment of B cell malignancies and autoimmune diseases.
  • WO2016007185 relates to a compound represented by formula I, namely (R)-4-amino-1-(1-(but-2-ynyl)pyrrolidin-3-yl)-3-(4-(2,6- Difluorophenoxy)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one, this compound is a new type of BTK kinase inhibitor, which is selective for kinases and clinical Efficacy, indications, and safety have been improved, and its structure is as follows:
  • WO2016007185 describes the preparation method of the compound represented by formula I, and the specific reaction is as follows:
  • the yield of multiple reaction steps is low and purification is difficult, so that the total yield of this route is low and the feasibility of scaling up is poor, and the palladium catalyst is used in the method, and the cost is high.
  • the purpose of the present disclosure is to provide a new preparation method of pyrroloaminopyridazinone compound.
  • One aspect of the present disclosure provides a method for preparing the compound represented by formula III, which includes the step of reacting the compound represented by formula II in the presence of an oxidizing agent,
  • R 1 is selected from a hydroxyl protecting group
  • R 2 is selected from hydrogen atom, alkyl group, halogen, hydroxyl, amino, Nitro, cyano, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl, the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally selected from halogen , Hydroxy, amino, oxy, carboxy, nitro, cyano, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl substituted by one or more substituents ;
  • R 3 is selected from hydrogen atom, alkyl group, halogen, -OR 4 , -NHR 4 , -NR 4 R 4 ';
  • R 4 and R 4 ' are each independently selected from hydrogen atom, alkyl group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group, wherein the alkyl group, carboxyl group, alkoxy group , Sulfonyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally selected from halogen, hydroxy, amino, oxy, carboxy, nitro, cyano, alkenyl, alkyne One or more substituents in the alkoxy group and alkoxy group; or R 4 , R 4 'and the N atom form a three- to eight-membered heterocyclic group or heteroaryl group, wherein the heterocyclic group or heteroaryl group The group is optionally substituted by one or more substituents selected from halogen, hydroxy, amino, oxy, carboxy, nitro, cyano, alken
  • R a is each independently selected from hydrogen atom, halogen, hydroxyl, nitro, cyano, carboxy, amino, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy or alkoxy;
  • A is selected from CR b and N, wherein R b is selected from a hydrogen atom, a halogen and an alkyl group, and the alkyl group is optionally selected from the group consisting of halogen, hydroxy, amino, oxy, carboxy, nitro, cyano, alkoxy , Cycloalkyl, alkenyl, alkynyl, heterocyclyl, aryl and heteroaryl substituted by one or more substituents;
  • B is selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein the alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group are optionally selected from One or more of alkyl, halogen, hydroxy, amino, oxy, carboxy, nitro, cyano, alkoxy, cycloalkyl, alkenyl, alkynyl, heterocyclic, aryl, and heteroaryl Substituent substituted;
  • L is an optionally substituted alkyl group, or not present.
  • Y is selected from optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted aralkyl and optionally substituted heteroaryl;
  • n 0, 1, 2, 3, or 4.
  • L is absent.
  • R 1 is selected from (C 1-10 alkyl or aryl) 3 silyl group, C 1-10 alkyl, alkoxy or aryl substituted alkyl, (C 1-10 alkane Group or aryl group) acyl group, (C 1-6 alkyl group or C 6-10 aryl group) sulfonyl group, (C 1-6 alkoxy group or C 6-10 aryloxy group) carbonyl group, preferably triethyl silicon Base, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, methyl, tert-butyl, allyl, benzyl, methoxymethyl (MOM), Ethoxyethyl, 2-tetrahydropyranyl (THP), formyl, acetyl, benzoyl.
  • MOM methoxymethyl
  • Ethoxyethyl 2-tetrahydropyranyl
  • THP
  • R 4 and R 4 ′ are each independently selected from a hydrogen atom or optionally substituted by halogen, hydroxy, amino, oxy, carboxy, nitro, cyano, alkenyl, alkynyl, and alkoxy.
  • the atom forms a five-membered or
  • B is selected from hydrogen, alkyl, aryl, and the alkyl and aryl are optionally selected from halogen, hydroxy, amino, oxy, carboxy, nitro, cyano, alkoxy , Cycloalkyl, heterocyclyl, aryl and heteroaryl substituted by one or more substituents.
  • B is a phenyl group substituted with at least one group selected from the following group: F, Cl, and methoxy.
  • B is phenyl substituted with two Fs.
  • B is phenyl substituted with two Cl.
  • B is phenyl substituted with one Cl and one methoxy group.
  • Y is optionally substituted with one or more of the following groups: (C 1-10 alkyl or aryl) acyl, (C 1-6 alkyl or C 6-10 aryl) )Sulfonyl, (C 1-6 alkoxy or C 6-10 aryloxy) carbonyl,
  • Y is selected from piperidinyl, phenyl, bicyclo[3.2.1]octyl, azetidinyl, and pyrrolidinyl, wherein piperidinyl, phenyl, bicyclo[ 3.2.1] Octyl, azetidinyl and pyrrolidinyl are optionally substituted with one or more of the following groups:
  • reactions connected by " ⁇ " all refer to a one-step reaction to obtain the product.
  • the compound represented by the formula II undergoes a one-step reaction to obtain the compound represented by the formula III.
  • the oxidant is selected from quinone oxidants, acid medium oxidants (such as hydrogen peroxide, peracetic acid, peroxybenzoic acid, sodium dichromate, chromic acid, nitric acid, potassium permanganate, permanganate). Ammonium sulfate, potassium hydrogen persulfate, sodium bromate), alkaline medium oxidants (such as sodium hypochlorite, sodium percarbonate, sodium perborate, potassium perborate), neutral oxidants (such as chlorine, bromine, iodine), preferably quinone oxidants .
  • acid medium oxidants such as hydrogen peroxide, peracetic acid, peroxybenzoic acid, sodium dichromate, chromic acid, nitric acid, potassium permanganate, permanganate.
  • Ammonium sulfate, potassium hydrogen persulfate, sodium bromate such as sodium hypochlorite, sodium percarbonate, sodium perborate, potassium perborate
  • neutral oxidants such as chlorine
  • the quinone oxidant is an oxidant containing quinone in the molecular structure, such as DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone); NQ (1,4-naphthoquinone) ; TCQ (2,3,4,5-tetrachloroquinone); TFQ (2,3,4,5-tetrafluoroquinone); BQ (1,4 benzoquinone); F4-TCNQ (2,3,5, 6-tetrafluoro-7,7,8,8-tetracyanoquinodimethane); TCNQ (7,7,8,8-tetracyanoquinodimethane); 2,3-dibromo-5,6- Dicyano-1,4-benzoquinone; 2,5-dichloro-3,6-dicyano-1,4-benzoquinone; 2,6-dichloro-3,5-dicyano-1, 4-benzoquinone; and 2,3-
  • the molar ratio of the compound represented by formula II to the oxidant may be 2:1 to 1:20, preferably 1:1 to 1:8.
  • the solvent used in the reaction can be a conventional solvent, such as water, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, xylene, dimethyl sulfoxide, diethyl ether, diisopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, C 1 ⁇ C 6 alkyl alcohol, acetone, ethyl acetate, one or more.
  • a conventional solvent such as water, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, xylene, dimethyl sulfoxide, diethyl ether, diisopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, C
  • the reaction temperature of the reaction may be -20°C to 200°C, preferably 0°C to 100°C.
  • the compound represented by formula II is selected from the compound represented by formula IIb,
  • R 1, R 2, definition of R a, A, m is as described above, R 5 is selected from a hydrogen atom, (C 1-10 alkyl or aryl group) acyl, (C 1-6 alkyl or C 6-10 aryl) sulfonyl, (C 1-6 alkoxy or C 6-10 aryloxy) carbonyl,
  • R c is each independently selected from hydrogen atom, halogen, hydroxyl, nitro, cyano, carboxy, amino, alkyl, haloalkyl, haloalkoxy or alkoxy;
  • n 0, 1, 2, 3, 4, or 5, and p is 1 or 2.
  • R 5 is selected from formyl, acetyl, benzoyl, Boc, Cbz, trityl (Tr), 2,4-dimethoxybenzyl (DMB), p-methoxy Benzyl (PMB), benzyl (Bn).
  • the compound represented by formula II is selected from compounds represented by formula IIc,
  • R 1 , R 3 , R 5 , R c , p, and n are as described above;
  • the compound represented by formula III is selected from compounds represented by formula IIIc,
  • R 3 , R 5 , R c , p, and n are as described above.
  • Another aspect of the present disclosure provides a method for preparing the compound represented by formula VIIc, which includes the steps of preparing the compound represented by formula IIIc as described in the present disclosure,
  • R 5 , R c , p and n are as described above.
  • the preparation method further includes the step of preparing the compound represented by formula IVc from the compound represented by formula IIIc,
  • Conventional oxidizing agents can be used to prepare carboxylic acids, such as sodium chlorite and the like.
  • the preparation method further includes the step of preparing the compound represented by formula IVc to the compound represented by formula Vc,
  • the preparation method further includes the step of preparing the compound represented by formula Vc to the compound represented by formula VIc,
  • R 6 is selected from alkyl, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl, alkylsulfonyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, preferably alkyl, more preferably ethyl base.
  • the preparation method further includes the step of preparing the compound represented by formula IVc from the compound represented by formula Vc',
  • R 6 is as described above.
  • the preparation method further includes the step of preparing the compound of formula VIc from the compound represented by formula Vc',
  • the preparation method further includes the step of preparing the compound represented by formula VIc from the compound represented by formula VIc,
  • Another aspect of the present disclosure provides a method for preparing a compound represented by formula I or a pharmaceutically acceptable salt thereof, which includes the steps of preparing a compound represented by formula VIIc described in the present disclosure,
  • the compound represented by the formula VIIc is selected from the compound represented by the formula VIIc', and R 5 is selected from the amino protecting group.
  • the preparation method further includes the step of preparing the compound represented by formula VIIIc' from the compound represented by formula VIIc',
  • the preparation method further includes the step of preparing the compound of formula I from the compound represented by formula VIIIc',
  • the preparation method includes
  • the preparation method further includes
  • the preparation method of the pyrroloaminopyridazinone compound described in the present disclosure combines the step of removing the hydroxyl protection group and the step of oxidizing the hydroxyl group to an aldehyde group into a one-step reaction.
  • the reaction conditions are mild, and the use of expensive catalysts is avoided. In addition to dangerous operations such as hydrogenation reaction, it is more suitable for industrial production.
  • alkyl mentioned in the present disclosure is preferably a C 1 -C 6 alkyl group.
  • alkenyl group mentioned in the present disclosure is preferably a C 2 -C 6 alkenyl group.
  • alkynyl mentioned in the present disclosure is preferably C 2 -C 6 alkynyl.
  • alkylene group mentioned in the present disclosure is preferably a C 1 -C 6 alkylene group.
  • alkenylene group mentioned in the present disclosure is preferably a C 2 -C 6 alkenylene group.
  • alkynylene group mentioned in the present disclosure is preferably a C 2 -C 6 alkynylene group.
  • alkoxy group mentioned in the present disclosure is preferably a C 1 -C 6 alkoxy group.
  • alkyl sulfide group described in the present disclosure is preferably a C 1 -C 6 alkyl sulfide group.
  • cycloalkyl group described in the present disclosure is preferably 3 to 12 membered, more preferably 3 to 6 membered cycloalkyl.
  • fused ring alkyl group is preferably 6 to 14 membered, and more preferably 7 to 10 membered fused ring alkyl.
  • heterocyclic group described in the present disclosure is preferably a 3- to 12-membered, more preferably a 3- to 6-membered heterocyclic group.
  • fused heterocyclic group is preferably 6 to 14 membered, and more preferably 7 to 10 membered fused heterocyclic group.
  • aryl group described in the present disclosure is preferably 6 to 14 membered, and more preferably 6 to 10 membered aryl group.
  • fused ring aryl group is preferably 8 to 14 membered, and more preferably 8 to 12 membered fused ring aryl.
  • heteroaryl group described in the present disclosure is preferably a 5- to 12-membered heteroaryl group, and more preferably a 5- to 10-membered heteroaryl group.
  • the "condensed heteroaryl group” described in the present disclosure is preferably a 5 to 14-membered, more preferably a 5 to 12-membered condensed heteroaryl group.
  • alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-Dimethylpropyl, 2,2-Dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylp
  • lower alkyl groups containing 1 to 6 carbon atoms More preferred are lower alkyl groups containing 1 to 6 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and sec-butyl.
  • Alkyl groups may be substituted or unsubstituted.
  • substituents When substituted, substituents may be substituted at any available attachment point.
  • the substituents are preferably one or more of the following groups, which are independently selected from alkanes Group, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy Group, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxy, or carboxylate.
  • alkylene refers to a saturated linear or branched aliphatic hydrocarbon group, which has two residues derived from the removal of two hydrogen atoms from the same carbon atom or two different carbon atoms of the parent alkane, which is A straight or branched chain group containing 1 to 20 carbon atoms, preferably containing 1 to 12 carbon atoms, more preferably an alkylene group containing 1 to 6 carbon atoms.
  • Non-limiting examples of alkylene include, but are not limited to, methylene (-CH 2 -), 1,1-ethylene (-CH(CH 3 )-), 1,2-ethylene (-CH 2 -) CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene (-CH 2 CH 2 CH 2 -), 1,4-butylene (-CH 2 CH 2 CH 2 CH 2 -), etc.
  • the alkylene group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
  • the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 Carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene Groups, cyclooctyl, etc.; polycyclic cycloalkyls include spiro, fused, and bridged cycloalkyls.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (wherein m is an integer of 0 to 2) heteroatoms, but does not include the ring part of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. It preferably contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 6 ring atoms.
  • Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidine Group, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc., preferably piperidinyl and pyrrolidinyl.
  • Polycyclic heterocyclic groups include spirocyclic, condensed, and bridged heterocyclic groups.
  • alkenyl includes branched and straight chain olefins having 2 to 12 carbon atoms or olefins containing aliphatic hydrocarbon groups.
  • C 2-6 alkenyl means an alkenyl group having 2, 3, 4, 5, or 6 carbon atoms.
  • alkenyl groups include, but are not limited to, vinyl, allyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylbut-2-alkenyl, 3-methylbut-1-alkenyl, 1-pentenyl, 3-pentenyl and 4-hexenyl.
  • alkynyl includes branched and straight chain alkynyl groups having 2 to 12 carbon atoms or olefins containing aliphatic hydrocarbon groups, or if the number of carbon atoms is specified, it means that specific number. For example, ethynyl, propynyl (for example, 1-propynyl, 2-propynyl), 3-butynyl, pentynyl, hexynyl, and 1-methylpent-2-ynyl.
  • aryl refers to a 6 to 14-membered all-carbon monocyclic or fused polycyclic (that is, rings sharing adjacent pairs of carbon atoms) with a conjugated ⁇ -electron system, preferably 6 to 10 members, such as benzene Base and naphthyl.
  • the aryl ring may be fused to a heteroaryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, and non-limiting examples thereof include:
  • the aryl group may be substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkane
  • a thio group, a carboxy group or a carboxylate group is preferably a phenyl group.
  • heteroaryl refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, where the heteroatoms are selected from oxygen, sulfur, and nitrogen.
  • Heteroaryl groups are preferably 5 to 12 members, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazine And the like, preferably imidazolyl, pyrazolyl, pyrimidinyl or thiazolyl; more preferably pyrazolyl or thiazolyl.
  • the heteroaryl ring may be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, non-limiting examples of which include:
  • Heteroaryl groups may be optionally substituted or unsubstituted.
  • the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio, carboxy, or carboxylate.
  • alkoxy refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where the definition of alkyl is as described above.
  • alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
  • the alkoxy group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio, carboxy, or carboxylate.
  • groups are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, Heterocycloalkylthio, carboxy, or carboxylate.
  • alkylthio refers to -S- (alkyl) and -S- (unsubstituted cycloalkyl), where the definition of alkyl is as described above.
  • alkylthio include methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio.
  • the alkylthio group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio,
  • the heterocycloalkylthio group is substituted by one or more substituents.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • Carboxy protecting group is a suitable group for carboxyl protection known in the art, see the carboxyl protecting group in the literature ("Protective Groups in Organic Synthesis", 5 Th Ed.TWGreene&P.GMWuts), as an example,
  • the carboxyl protecting group can be a substituted or unsubstituted C 1-10 linear or branched alkyl group, a substituted or unsubstituted C 2-10 linear or branched alkenyl or alkynyl group, A substituted or unsubstituted C 3-8 cyclic alkyl group, a substituted or unsubstituted C 5-10 aryl or heteroaryl group, or a (C 1-8 alkyl or aryl) 3 silyl group; preferably C A 1-6 linear or branched alkyl group, more preferably a C 1-4 linear or branched alkyl group.
  • amino protecting group is an appropriate group for protecting amino group known in the art, see the amino protecting group in the literature ("Protective Groups in Organic Synthesis", 5 Th. Ed. TW Greene & P. GMWuts), preferably ,
  • the amino protecting group can be (C 1-10 alkyl or aryl) acyl, such as formyl, acetyl, benzoyl, etc.; it can be (C 1-6 alkyl or C 6-10 aryl).
  • sulfonyl can also be (C 1-6 alkoxy or C 6-10 aryloxy) carbonyl, such as Boc or Cbz; it can also be substituted or unsubstituted alkyl, such as trityl Group (Tr), 2,4-dimethoxybenzyl (DMB), p-methoxybenzyl (PMB) or benzyl (Bn).
  • Tr trityl Group
  • DMB 2,4-dimethoxybenzyl
  • PMB p-methoxybenzyl
  • Bn benzyl
  • hydroxyl protecting group is a suitable group for protecting the hydroxyl group known in the art, see the literature ("Protective Groups in Organic Synthesis", 5 Th Ed. TW Greene & P. GMWuts) for the hydroxyl protecting group.
  • the hydroxy protecting group can be (C 1-10 alkyl or aryl) 3 silyl group, for example: triethylsilyl, triisopropylsilyl, tert-butyldimethyl Silyl, tert-butyldiphenylsilyl, etc.; can be C 1-10 alkyl or substituted alkyl, preferably alkoxy or aryl substituted alkyl, more preferably C 1-6 alkoxy substituted C C 1-6 alkyl substituted with 1-6 alkyl or phenyl, most preferably C 1-4 alkyl substituted with C 1-4 alkoxy, for example: methyl, tert-butyl, allyl, benzyl , Methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), etc.; can be (C 1-10 alkyl or aryl) acyl, such as formyl, acetyl ,
  • heterocyclic group optionally substituted by an alkyl group means that an alkyl group may but need not be present, and the description includes the case where the heterocyclic group is substituted by an alkyl group and the case where the heterocyclic group is not substituted by an alkyl group.
  • the bond The configuration is not specified, that is, if there is configurational isomerism in the chemical structure, the bond Can be or Or both with Two configurations.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本公开涉及一种吡咯并氨基哒嗪酮化合物的制备方法。具体而言,本公开涉及一种如式(III)所示化合物的制备方法,包括式II所示化合物在氧化剂存在的条件下反应的步骤,其中式(II)和式(III)所示化合物的各取代基与说明书中的定义相同。该方法收率高、产物纯度好、反应条件温和。

Description

一种吡咯并氨基哒嗪酮化合物的制备方法 技术领域
本公开属于医药领域,涉及一种吡咯并氨基哒嗪酮化合物的制备方法。
背景技术
免疫细胞通常可以分为T细胞与B细胞两类,其中B细胞的主要职能是分泌各种抗体帮助人体抵御各种外来的侵入。Bruton酪氨酸蛋白激酶(BTK)是酪氨酸蛋白激酶亚家族的成员之一,属于Tec家族激酶,主要在B细胞中表达,分布于淋巴系统、造血及血液系统。B细胞受体(BCR)对于包括慢性淋巴细胞性白血病(CLL)和非霍奇金淋巴瘤的(NHL)亚型,套细胞淋巴瘤(MCL),和弥漫性大B细胞淋巴瘤(DLBCL)在内的多种淋巴瘤的增殖及生存具有至关重要的调控作用,此外,B细胞在类风湿关节炎,系统性红斑狼疮,多发性硬化症,以及其他免疫疾病的发病机制中的作用已被临床证实。Bruton酪氨酸蛋白激酶(BTK)是BCR信号通路中的一个关键的蛋白激酶。能够调节正常B细胞的成熟、分化,也与多种B细胞淋巴组织失调疾病密切相关。因此,靶向小分子抑制剂BTK可对B细胞恶性肿瘤和自身免疫疾病的治疗提供效益。
WO2016007185涉及一种式I所示化合物,即(R)-4-氨基-1-(1-(丁-2-炔酰基)吡咯烷-3-基)-3-(4-(2,6-二氟苯氧基)苯基)-1,6-二氢-7H-吡咯并[2,3-d]哒嗪-7-酮,该化合物为新型BTK激酶抑制剂,在激酶选择性,临床疗效或适应症,及安全性等方面均有所改善,其结构如下所示:
Figure PCTCN2020118309-appb-000001
WO2016007185记载了式I所示化合物的制备方法,具体反应如下所示:
Figure PCTCN2020118309-appb-000002
整个方法中存在多个反应步骤的产率偏低、纯化困难,使得该路线的总收率较低且放大可行性较差,并且方法中用到钯催化剂,成本较高。
发明内容
本公开的目的在于提供一种新的吡咯并氨基哒嗪酮化合物的制备方法。
本公开一方面提供如式III所示化合物的制备方法,包括式II所示化合物在氧化剂存在的条件下反应的步骤,
Figure PCTCN2020118309-appb-000003
其中,
R 1选自羟基保护基;
R 2选自氢原子、烷基、卤素、羟基、氨基、
Figure PCTCN2020118309-appb-000004
硝基、氰基、烷氧基、环烷基、杂环基、芳基和杂芳基,所述烷基、环烷基、杂环基、芳基和杂芳基任选被选自卤素、羟基、氨基、氧基、羧基、硝基、氰基、烯基、炔基、烷氧基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;
R 3选自氢原子、烷基、卤素、-OR 4、-NHR 4、-NR 4R 4’;
R 4、R 4’各自独立地选自氢原子、烷基、烯基、炔基、环烷基、杂环基、芳基和杂芳基,其中所述的烷基、羧基、烷氧基、磺酰基、烯基、炔基、环烷基、杂环基、芳基和杂芳基任选被选自卤素、羟基、氨基、氧基、羧基、硝基、氰基、烯基、炔基、烷氧基中的一个或多个取代基所取代;或R 4、R 4’与N原子形成三元至八元杂环基或杂芳基,其中所述的杂环基或杂芳基任选被选自卤素、羟基、氨基、氧基、羧基、硝基、氰基、烯基、炔基、烷氧基中的一个或多个取代基所取代;
R a各自独立地选自氢原子、卤素、羟基、硝基、氰基、羧基、氨基、烷基、烯基、炔基、卤代烷基、卤代烷氧基或烷氧基;
A选自C-R b和N,其中R b选自氢原子、卤素和烷基,所述烷基任选被选自卤素、羟基、氨基、氧基、羧基、硝基、氰基、烷氧基、环烷基、烯基、炔基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;
B选自氢原子、烷基、环烷基、杂环基、芳基和杂芳基,其中所述的烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤素、羟基、氨基、氧基、羧基、硝基、氰基、烷氧基、环烷基、烯基、炔基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;
L是任选被取代的烷基,或者不存在;并且,
Y选自任选被取代的环烷基、任选被取代的杂环基、任选被取代的芳基、任选被取代的芳烷基和任选被取代的杂芳基;
m为0、1、2、3或4。
在某些实施方式中,L不存在。
在某些实施方式中,R 1选自(C 1-10烷基或芳基) 3硅烷基、C 1-10烷基、烷氧基或芳基取代的烷基、(C 1-10烷基或芳香基)酰基、(C 1-6烷基或C 6-10芳基)磺酰基、(C 1-6烷氧基或C 6-10芳基氧基)羰基,优选三乙基硅基、三异丙基硅基、叔丁基二甲基硅基、叔丁基二苯基硅基、甲基、叔丁基、烯丙基、苄基、甲氧基甲基(MOM)、乙氧基乙基、2-四氢吡喃基(THP)、甲酰基、乙酰基、苯甲酰基。
在某些实施方式中,R 4、R 4’各自独立地选自氢原子或任选被卤素、羟基、氨 基、氧基、羧基、硝基、氰基、烯基、炔基、烷氧基中的一个或多个取代基所取代的以下基团:烷基、羧基、烷氧基、磺酰基、烯基、环烷基、苯基、萘基、吡咯烷基、咪唑烷基、四氢呋喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基、咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基;或R 4、R 4’与N原子形成任选被卤素、羟基、氨基、氧基、羧基、硝基、氰基、烯基、炔基、烷氧基中的一个或多个取代基所取代的五元或六元杂环基、杂芳基。
在某些实施方式中,B选自氢、烷基、芳基,所述烷基、芳基任选被选自卤素、羟基、氨基、氧基、羧基、硝基、氰基、烷氧基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代。在一些实施方式中,B是被选自以下组中的至少一个基团取代的苯基:F、Cl和甲氧基。在一些实施方式中,B是被两个F取代的苯基。在一些实施方式中,B是被两个Cl取代的苯基。在一些实施方式中,B是被一个Cl和一个甲氧基取代的苯基。
在某些实施方式中,Y任选被以下基团中的一种或多种取代:(C 1-10烷基或芳香基)酰基、(C 1-6烷基或C 6-10芳基)磺酰基、(C 1-6烷氧基或C 6-10芳基氧基)羰基、
卤素、CN、CH 3-O-、-C(O)CH=CH 2、-C(O)CH=CHCH 2N(CH 3) 2、-NHC(O)CH=CH 2、-NHC(O)CH=CHCH 2N(CH 3) 2
-C(O)CH=CHCH 2N(CH 3)(COOC(CH 3) 3;-C(O)CH=CHCH 2NH(CH 3)、-C(O)CH 2CH 3
-C(O)CH 2CH 2CH 3
Figure PCTCN2020118309-appb-000005
-C(O)CH 2CN、
Figure PCTCN2020118309-appb-000006
Figure PCTCN2020118309-appb-000007
在某些实施方式中,Y选自哌啶基、苯基、二环[3.2.1]辛烷基、氮杂环丁烷基和吡咯烷基,其中哌啶基、苯基、二环[3.2.1]辛烷基、氮杂环丁烷基和吡咯烷基任选被以下基团中的一种或多种取代:
(C 1-10烷基或芳香基)酰基、(C 1-6烷基或C 6-10芳基)磺酰基、(C 1-6烷氧基或C 6-10芳基氧基)羰基、
卤素、CN、CH 3-O-、-C(O)CH=CH 2、-C(O)CH=CHCH 2N(CH 3) 2、-NHC(O)CH=CH 2、-NHC(O)CH=CHCH 2N(CH 3) 2
-C(O)CH=CHCH 2N(CH 3)(COOC(CH 3) 3;-C(O)CH=CHCH 2NH(CH 3)、-C(O)CH 2CH 3
-C(O)CH 2CH 2CH 3
Figure PCTCN2020118309-appb-000008
-C(O)CH 2CN、
Figure PCTCN2020118309-appb-000009
Figure PCTCN2020118309-appb-000010
本公开所述的制备方法中,通过“→”连接的反应均指一步反应即得到所述的产物。例如,所述的式III所示化合物的制备方法中,式II所示化合物经一步反应即得到式III所示化合物。
在某些实施方式中,所述氧化剂选自醌类氧化剂、酸性介质氧化剂(如过氧化氢、过氧乙酸、过氧苯甲酸、重铬酸钠、铬酸、硝酸、高锰酸钾、过硫酸铵、过硫酸氢钾、溴酸钠)、碱性介质氧化剂(如次氯酸钠、过碳酸钠、过硼酸钠、过硼酸钾)、中性氧化剂(如氯、溴、碘),优选醌类氧化剂。
所述的醌类氧化剂为分子结构中含醌的氧化剂,例如DDQ(2,3-二氯-5,6-二氰基-1,4-苯醌);NQ(1,4-萘醌);TCQ(2,3,4,5-四氯醌);TFQ(2,3,4,5-四氟醌);BQ(1,4苯醌);F4-TCNQ(2,3,5,6-四氟-7,7,8,8-四氰基醌二甲 烷);TCNQ(7,7,8,8-四氰基醌二甲烷);2,3-二溴-5,6-二氰基-1,4-苯醌;2,5-二氯-3,6-二氰基-1,4-苯醌;2,6-二氯-3,5-二氰基-1,4-苯醌;和2,3-二碘-5,6-二氰基-1,4-苯醌及其各种络合物等,优选DDQ。
在某些实施方式中,式II所示化合物与氧化剂的摩尔比可以是2:1~1:20,优选1:1~1:8。
所述反应使用的溶剂可以是常规溶剂,例如水、二甲基甲酰胺、1-甲基-2-吡咯烷酮、四氢呋喃、甲基四氢呋喃、二氧六环、甲苯、二甲苯、二甲亚砜、乙醚、异丙醚、甲基叔丁基醚、乙腈、丙腈、C 1~C 6烷基醇、丙酮、乙酸乙酯中的一种或多种。
所述反应的反应温度可以是-20℃~200℃,优选0℃~100℃。
在某些实施方式中,所述式II所示化合物选自式IIb所示化合物,
Figure PCTCN2020118309-appb-000011
其中,R 1、R 2、R a、A、m的定义如前所述,R 5选自氢原子、(C 1-10烷基或芳香基)酰基、(C 1-6烷基或C 6-10芳基)磺酰基、(C 1-6烷氧基或C 6-10芳基氧基)羰基、
卤素、CN、CH 3-O-、-C(O)CH=CH 2、-C(O)CH=CHCH 2N(CH 3) 2、-NHC(O)CH=CH 2、-NHC(O)CH=CHCH 2N(CH 3) 2
-C(O)CH=CHCH 2N(CH 3)(COOC(CH 3) 3;-C(O)CH=CHCH 2NH(CH 3)、-C(O)CH 2CH 3
-C(O)CH 2CH 2CH 3
Figure PCTCN2020118309-appb-000012
-C(O)CH 2CN、
Figure PCTCN2020118309-appb-000013
Figure PCTCN2020118309-appb-000014
Figure PCTCN2020118309-appb-000015
R c各自独立地选自氢原子、卤素、羟基、硝基、氰基、羧基、氨基、烷基、卤代烷基、卤代烷氧基或烷氧基;
n为0、1、2、3、4或5,p为1或2。
在某些实施方式中,R 5选自甲酰基、乙酰基、苯甲酰基、Boc、Cbz、三苯甲基(Tr)、2,4-二甲氧基苄基(DMB)、对甲氧基苄基(PMB)、苄基(Bn)。
在某些实施方式中,所述式II所示化合物选自式IIc所示化合物,
Figure PCTCN2020118309-appb-000016
其中,R 1、R 3、R 5、R c、p、n的定义如前所述;
所述式III所示化合物选自式IIIc所示化合物,
Figure PCTCN2020118309-appb-000017
其中,R 3、R 5、R c、p、n的定义如前所述。
本公开另一方面提供了一种制备式VIIc所示化合物的制备方法,包括本公开所述的制备式IIIc所示化合物的步骤,
Figure PCTCN2020118309-appb-000018
其中,R 5、R c、p、n的定义如前所述。
在某些实施方式中,所述制备方法还包括式IIIc所示化合物制备式IVc所示化合物的步骤,
Figure PCTCN2020118309-appb-000019
可以使用常规的氧化剂制备羧酸,例如亚氯酸钠等。
在某些实施方式中,所述制备方法还包括式IVc所示化合物制备式Vc所示化合物的步骤,
Figure PCTCN2020118309-appb-000020
在某些实施方式中,所述制备方法还包括式Vc所示化合物制备式VIc所示化合物的步骤,
Figure PCTCN2020118309-appb-000021
其中,R 6选自烷基、烷基羰基、烷氧基羰基、烷基氨基羰基、烷基磺酰基、环烷基、杂环基、芳基或杂芳基,优选烷基,更优选乙基。
在某些实施方式中,所述制备方法还包括式IVc所示化合物制备式Vc’所示化合物的步骤,
Figure PCTCN2020118309-appb-000022
其中,R 6的定义如前所述。
在某些实施方式中,所述制备方法还包括式Vc’所示化合物制备式VIc所示化合物的步骤,
Figure PCTCN2020118309-appb-000023
在某些实施方式中,所述制备方法还包括式VIc所示化合物制备式VIIc所示化合物的步骤,
Figure PCTCN2020118309-appb-000024
本公开另一方面提供了一种制备式I所示化合物或其可药用盐的制备方法,包括本公开所述的制备式VIIc所示化合物的步骤,
Figure PCTCN2020118309-appb-000025
其中,式VIIc所示化合物选自式VIIc’所示化合物,R 5选自氨基保护基。
在某些实施方式中,所述制备方法还包括式VIIc’所示化合物制备式VIIIc’所示化合物的步骤,
Figure PCTCN2020118309-appb-000026
在某些实施方式中,所述制备方法还包括式VIIIc’所示化合物制备式I所示化合物的步骤,
Figure PCTCN2020118309-appb-000027
在某些实施方式中,所述制备方法包括
Figure PCTCN2020118309-appb-000028
在某些实施方式中,所述制备方法还包括
Figure PCTCN2020118309-appb-000029
本公开所述的吡咯并氨基哒嗪酮化合物的制备方法,将脱除羟基保护基的步骤与羟基氧化为醛基的步骤合并为一步反应,反应条件温和,且避免了使用昂贵的催化剂,避免了加氢反应等危险操作,更加适合工业化生产。
本公开所述的“烷基”优选C 1-C 6烷基。
本公开所述的“烯基”优选C 2-C 6烯基。
本公开所述的“炔基”优选C 2-C 6炔基。
本公开所述的“亚烷基”优选C 1-C 6亚烷基。
本公开所述的“亚链烯基”优选C 2-C 6亚链烯基。
本公开所述的“亚链炔基”优选C 2-C 6亚链炔基。
本公开所述的“烷氧基”优选C 1-C 6烷氧基。
本公开所述的“烷硫醚基”优选C 1-C 6烷硫醚基。
本公开所述的“环烷基”优选3至12元,更优选3至6元环烷基。
本公开所述的“稠环烷基”优选为6至14元,更优选为7至10元稠环烷基。
本公开所述的“杂环基”优选3至12元,更优选3至6元杂环基。
本公开所述的“稠杂环基”优选6至14元,更优选为7至10元稠杂环基。
本公开所述的“芳基”优选为6至14元,更优选为6至10元芳基。
本公开所述的“稠环芳基”优选8至14元,更优选为8至12元稠环芳基。
本公开所述的“杂芳基”优选为5至12元,更优选为5至10元杂芳基。
本公开所述的“稠杂芳基”优选为5至14元,更优选为5至12元稠杂芳基。
除非有相反陈述,在说明书和权利要求书中使用的术语具有下述含义。
术语“烷基”指饱和脂肪族烃基团,其为包含1至20个碳原子的直链或支链基团,优选含有1至12个碳原子的烷基。非限制性实例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲 基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基,及其各种支链异构体等。更优选的是含有1至6个碳原子的低级烷基,非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。烷基可以是取代的或非取代的,当被取代时,取代基可以在任何可使用的连接点上被取代,所述取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、氧代基、羧基或羧酸酯基。
术语“亚烷基”指饱和的直链或支链脂肪族烃基,其具有2个从母体烷的相同碳原子或两个不同的碳原子上除去两个氢原子所衍生的残基,其为包含1至20个碳原子的直链或支链基团,优选含有1至12个碳原子,更优选含有1至6个碳原子的亚烷基。亚烷基的非限制性实例包括但不限于亚甲基(-CH 2-)、1,1-亚乙基(-CH(CH 3)-)、1,2-亚乙基(-CH 2CH 2)-、1,1-亚丙基(-CH(CH 2CH 3)-)、1,2-亚丙基(-CH 2CH(CH 3)-)、1,3-亚丙基(-CH 2CH 2CH 2-)、1,4-亚丁基(-CH 2CH 2CH 2CH 2-)等。亚烷基可以是取代的或非取代的,当被取代时,取代基可以在任何可使用的连接点上被取代。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基,环烷基环包含3至20个碳原子,优选包含3至12个碳原子,更优选包含3至6个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等;多环环烷基包括螺环、稠环和桥环的环烷基。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基,其包含3至20个环原子,其中一个或多个环原子为选自氮、氧或S(O) m(其中m是整数0至2)的杂原子,但不包括-O-O-、-O-S-或-S-S-的环部分,其余环原子为碳。优选包含3至12个环原子,其中1~4个是杂原子;更优选包含3至6个环原子。单环杂环基的非限制性实例包括吡咯烷基、咪唑烷基、四氢呋喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基等,优选哌啶基、吡咯烷基。多环杂环基包括螺环、稠环和桥环的杂环基。
术语“烯基”包括具有2至12个碳原子的支链和直链烯烃或含有脂族烃基团的烯烃。例如“C 2‐6烯基”表示具有2、3、4、5或6个碳原子的烯基。烯基的实例包括但不限于,乙烯基、烯丙基、1‐丙烯基、1‐丁烯基、2‐丁烯基、3‐丁烯基、2‐甲基丁‐2‐烯基、3‐甲基丁‐1‐烯基、1‐戊烯基、3‐戊烯基及4‐己烯基。
术语“炔基”包括具有2至12个碳原子的支链和直链炔基或含有脂族烃基的烯烃,或若规定指定碳原子数,则意指该特定数目。例如乙炔基、丙炔基(例如1‐丙炔基、2‐丙炔基)、3‐丁炔基、戊炔基、己炔基及1‐甲基戊‐2‐炔基。
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团,优选为6至10元,例如苯基和萘基。所述芳基环可以稠合于杂芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为芳基环,其非限制性实例包括:
Figure PCTCN2020118309-appb-000030
芳基可以是取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基,优选苯基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系,其中杂原子选自氧、硫和氮。杂芳基优选为5至12元,例如咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基等,优选为咪唑基、吡唑基、嘧啶基或噻唑基;更优选为吡唑基或噻唑基。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为杂芳基环,其非限制性实例包括:
Figure PCTCN2020118309-appb-000031
杂芳基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基),其中烷基的定义如上所述。烷氧基的非限制性实例包括:甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。烷氧基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基、羧基或羧酸酯基。
术语“烷硫基”指-S-(烷基)和-S-(非取代的环烷基),其中烷基的定义如上所述。烷硫基的非限制性实例包括:甲硫基、乙硫基、丙硫基、丁硫基、环丙硫基、环丁硫基、环戊硫基、环己硫基。烷硫基可以是任选取代的或非取代的,当被取代时,取代基优选为一个或多个以下基团,其独立地选自烷基、烯基、炔基、烷氧基、烷硫基、烷基氨基、卤素、巯基、羟基、硝基、氰基、环烷基、杂环基、芳基、杂芳基、环烷氧基、杂环烷氧基、环烷硫基、杂环烷硫基中的一个或多个取代基所取代。
术语“卤素”指氟、氯、溴或碘。
“羧基保护基”是本领域已知的适当的用于羧基保护的基团,参见文献(“Protective Groups in Organic Synthesis”,5 Th Ed.T.W.Greene&P.G.M.Wuts)中的羧基保护基团,作为示例,优选地,所述的羧基保护基可以是取代或非取代的C 1-10的直链或支链烷基、取代或非取代的C 2-10的直链或支链烯基或炔基、取代或非取代的C 3-8的环状烷基、取代或非取代的C 5-10的芳基或杂芳基、或(C 1-8烷基或芳基) 3硅烷基;优选C 1-6的直链或支链烷基,更优选C 1-4的直链或支链烷基。例如,甲基、乙基、烯丙基、异戊烯基、三甲基硅基乙基等。
“氨基保护基”是本领域已知的适当的用于氨基保护的基团,参见文献(“Protective Groups in Organic Synthesis”,5 Th.Ed.T.W.Greene&P.G.M.Wuts)中的氨基保护基团,优选地,所述的氨基保护基可以是(C 1-10烷基或芳香基)酰基,例如:甲酰基,乙酰基,苯甲酰基等;可以是(C 1-6烷基或C 6-10芳基)磺酰基;也可以是(C 1-6烷氧基或C 6-10芳基氧基)羰基,例如:Boc或Cbz;还可以是取代或非取代的烷基,例如:三苯甲基(Tr)、2,4-二甲氧基苄基(DMB)、对甲氧基苄基(PMB)或苄基(Bn)。
“羟基保护基”是本领域已知的适当的用于羟基保护的基团,参见文献(“Protective Groups in Organic Synthesis”,5 Th Ed.T.W.Greene&P.G.M.Wuts)中的羟基保护基团。作为示例,优选地,所述的羟基保护基可以是(C 1-10烷基或芳基) 3硅烷基,例如:三乙基硅基,三异丙基硅基,叔丁基二甲基硅基,叔丁基二苯基 硅基等;可以是C 1-10烷基或取代烷基,优选烷氧基或芳基取代的烷基,更优选C 1-6烷氧基取代的C 1-6烷基或苯基取代的C 1-6烷基,最优选C 1-4烷氧基取代的C 1-4烷基,例如:甲基,叔丁基,烯丙基,苄基,甲氧基甲基(MOM),乙氧基乙基,2-四氢吡喃基(THP)等;可以是(C 1-10烷基或芳香基)酰基,例如:甲酰基,乙酰基,苯甲酰基等;可以是(C 1-6烷基或C 6-10芳基)磺酰基;也可以是(C 1-6烷氧基或C 6-10芳基氧基)羰基。
“任选”或“任选地”意味着随后所描述地事件或环境可以但不必发生,该说明包括该事件或环境发生或不发生地场合。例如,“任选被烷基取代的杂环基团”意味着烷基可以但不必须存在,该说明包括杂环基团被烷基取代的情形和杂环基团不被烷基取代的情形。
本公开所述化合物的化学结构中,键
Figure PCTCN2020118309-appb-000032
并未指定构型,即如果化学结构中存在构型异构,键
Figure PCTCN2020118309-appb-000033
可以为
Figure PCTCN2020118309-appb-000034
Figure PCTCN2020118309-appb-000035
或者同时包含
Figure PCTCN2020118309-appb-000036
Figure PCTCN2020118309-appb-000037
两种构型。
具体实施方式
以下将结合具体实例详细地解释本公开,使得本专业技术人员更全面地理解本公开具体实例仅用于说明本公开的技术方案,并不以任何方式限定本公开。
实施例1
Figure PCTCN2020118309-appb-000038
氮气保护下,将化合物1(20g)、叔丁基胺(9.91g)、4-二甲氨基吡啶(5.17g)加入的甲苯(400mL)中,反应液升温至回流搅拌,反应结束后,经柱层析(洗脱剂为石油醚:乙酸乙酯=5:1)分离得到目标化合物3(16.6g,产率74.5%)。
实施例2
Figure PCTCN2020118309-appb-000039
反应瓶中加入乙酸(2600mL)、乙酸铵(411.42g),搅拌溶解,加入化合物2(500g)的硝基甲烷(912.2g)溶液,升温至90℃,保温反应。反应结束后,降温,加入水(5.2L),搅拌析晶,过滤得粗品662g;加入异丙醇(2.5L)重结晶,过滤,干燥得产物4(443g,产率74.9%)。
实施例3
Figure PCTCN2020118309-appb-000040
氮气保护下,在500mL干燥三口瓶中加入3(11.4g,43.3mmol),4(10g,36.1mmol),5(9.41g,50.5mmol),加入甲苯(150mL)和分子筛20g,硝基甲烷(22g,0.36mol.),无水三氯化铁(1.17g,7.2mmol),搅拌,将反应液升温至100℃,搅拌反应。反应结束后,降至室温,过滤,用MTBE洗涤滤饼,合并滤液并浓缩,然后加入150mL MTBE溶解,用1M盐酸溶液、1M NaOH溶液、10%氯化铵溶液、饱和食盐水分别洗涤有机相。减压浓缩有机相,得到35g化合物6粗品。
1H-NMR(400MHz,CDCl 3)δ7.38-7.26(m,8H),7.19-7.12(m,1H),7.05-6.94(m,4H),6.61(s,1H),5.21(s,1H),4.91-4.83(m,2H),4.58(s,2H),3.87-3.43(m,4H),2.27-2.04(m,2H),1.45(s,9H),1.19(s,9H).
实施例4
Figure PCTCN2020118309-appb-000041
将上步得到的化合物6粗品(35g)加入到500mL三口瓶中,然后加入甲苯(150mL)和水(15mL),升温至80℃,然后加入DDQ(20.5g),加完保温搅拌反应。反应结束后经柱层析(洗脱剂为石油醚:乙酸乙酯=5:1)分离得到化合物7共12.4g(两步收率60.8%)。
1H-NMR(400MHz,CDCl 3)δ10.12(d,1H),7.32(d,2H),7.26-7.14(m,1H),7.06-6.95(m,5H),5.82(s,1H),5.29(s,1H),3.83-3.52(m,4H),2.45-2.40(m,1H),2.18-2.12(m,1H),1.46(s,9H),1.19(s,9H).
实施例5
Figure PCTCN2020118309-appb-000042
第一步、化合物8的合成
反应瓶中加入化合物7(26.0g)、叔丁醇(500mL)、异戊烯(57.6mL),搅拌溶解,将亚氯酸钠(20.7g)和磷酸二氢钠(12.4g)溶解于水(100mL)中,滴入到上述反应液中,于20℃下搅拌反应,反应完全后浓缩,加入水(300mL),再用甲基叔丁基醚萃取,合并有机相,用水洗涤有机相,经无水硫酸钠干燥,过滤,浓缩得产物化合物8(28.3g,产率105.8%)。
第二步、化合物9的合成
反应瓶中加入化合物8(28.3g)和二氯甲烷(400mL),将三氟乙酸酐(20.4g)溶解在二氯甲烷(160mL)中,滴入到上述反应体系中,滴毕后,室温反应,反应完全后,加入200mL的水,分液,水相再用二氯甲烷萃取,合并有机相,水洗至中性,经无水硫酸镁干燥,过滤,浓缩得粗品(25.0g,产率100%)。
将所得25.0g粗品产物溶解在甲基叔丁基醚(200mL)中,将叔丁胺(6.2mL)稀释在甲基叔丁基醚(50mL)中,缓慢滴入到上述体系中,于室温下搅拌,抽滤,甲基叔丁基醚洗涤滤饼,真空干燥,得到化合物9(21.5g,产率75%,纯度94.1%)。
第三步、化合物10的合成
反应瓶中加入化合物9的叔丁胺盐(21.5g)、碳酸钾(15.3g)和N,N-二甲基甲酰胺(200mL),冰水冷却下,加入碘乙烷(8.8mL),滴毕后,撤去冰浴,于30℃下反应。反应结束后,加入水(200mL),用甲基叔丁基醚萃取,合并有机相,用水洗涤有机相,经无水硫酸钠干燥,过滤,浓缩得化合物10(18.5g,产率91%)。
第四步、化合物11的合成
反应瓶中加入化合物10(6.0g)、水合肼(35mL)和乙醇(60mL),氮气保护,将反应液加热至回流进行反应,反应完全后,冷却至室温,体系浓缩,加入饱和氯 化钠水溶液,用乙酸乙酯萃取,合并有机相,用水洗涤,有机相经无水硫酸钠干燥,过滤,经硅胶柱层析(洗脱剂为洗脱剂为石油醚:乙酸乙酯=2:1)进行纯化,得化合物11(4.5g,产率78.7%)。
第五步、化合物12的合成
反应瓶中加入化合物11(4.5g)和甲醇(50mL),搅拌溶解,冰水冷却下,加入6N盐酸(40mL),撤去冰浴,于25℃下反应至原料消耗完全,体系浓缩,用NaOH调节pH至10左右,再用二氯甲烷萃取,合并有机相,用水洗涤,有机相经无水硫酸镁干燥,过滤,浓缩去除溶剂,得化合物12(3.2g,纯度>99%,产率88.0%)。
第六步、式I所示化合物的合成
反应瓶中加入化合物12(3.2g)和二氯甲烷(33mL),于冰水浴下加入丁炔酸(0.95g)、EDCI(2.9g)和三乙胺(3.2mL),在20℃下搅拌反应至原料消耗完全,加入水(100mL)淬灭反应,水相用二氯甲烷萃取,合并有机相,经无水硫酸钠干燥,过滤,经硅胶柱层析纯化(洗脱剂为洗脱剂为石油醚:乙酸乙酯=2:1)得到式I所示化合物(3.2g,产率86.0%,纯度98.3%)。
1H-NMR(400MHz,CDCl 3)δ11.5(br,1H),7.38-7.40(d,2H),7.16-7.24(m,1H),7.02-7.08(m,5H),6.34-6.38(m,1H),5.30-5.32(br,2H),4.19-4.24(m,0.5H),3.69-3.98(m,3.5H),2.53-2.58(m,1H),2.31-2.37(m,1H),1.96-2.02(d,3H).
由于已根据其特殊的实施方案描述了本公开,某些修饰和等价变化对于精通此领域的技术人员是显而易见的且包括在本公开的范围内。

Claims (22)

  1. 一种如式III所示化合物的制备方法,包括式II所示化合物在氧化剂存在的条件下反应的步骤,
    Figure PCTCN2020118309-appb-100001
    其中:
    R 1选自羟基保护基;
    R 2选自氢原子、烷基、卤素、羟基、氨基、
    Figure PCTCN2020118309-appb-100002
    硝基、氰基、烷氧基、环烷基、杂环基、芳基和杂芳基,所述烷基、环烷基、杂环基、芳基和杂芳基任选被选自卤素、羟基、氨基、氧基、羧基、硝基、氰基、烯基、炔基、烷氧基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;
    R 3选自氢原子、烷基、卤素、-OR 4、-NHR 4、-NR 4R 4’;
    R 4、R 4’各自独立地选自氢原子、烷基、羧基、烷氧基、磺酰基、烯基、炔基、环烷基、杂环基、芳基和杂芳基,其中所述的烷基、羧基、烷氧基、磺酰基、烯基、炔基、环烷基、杂环基、芳基和杂芳基任选被选自卤素、羟基、氨基、氧基、羧基、硝基、氰基、烯基、炔基、烷氧基中的一个或多个取代基所取代;或R 4、R 4’与N原子形成三元至八元杂环基或杂芳基,其中所述的杂环基或杂芳基任选被选自卤素、羟基、氨基、氧基、羧基、硝基、氰基、烯基、炔基、烷氧基中的一个或多个取代基所取代;
    R a各自独立地选自氢原子、卤素、羟基、硝基、氰基、羧基、氨基、烷基、烯基、炔基、卤代烷基、卤代烷氧基或烷氧基;
    A选自C-R b和N,其中R b选自氢原子、卤素和烷基,所述烷基任选被选自卤素、羟基、氨基、氧基、羧基、硝基、氰基、烷氧基、环烷基、烯基、炔基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;
    B选自氢原子、烷基、环烷基、杂环基、芳基和杂芳基,其中所述的烷基、环烷基、杂环基、芳基和杂芳基任选被选自烷基、卤素、羟基、氨基、氧基、羧基、硝基、氰基、烷氧基、环烷基、烯基、炔基、杂环基、芳基和杂芳基中的一个或多个取代基所取代;
    L是任选被取代的烷基,或者不存在;并且,
    Y选自任选被取代的环烷基、任选被取代的杂环基、任选被取代的芳基、任选 被取代的芳烷基和任选被取代的杂芳基;
    m为0、1、2、3或4。
  2. 根据权利要求1所述的制备方法,其中R 1选自(C 1-10烷基或芳基) 3硅烷基、C 1-10烷基、烷氧基或芳基取代的烷基、(C 1-10烷基或芳香基)酰基、(C 1-6烷基或C 6-10芳基)磺酰基、(C 1-6烷氧基或C 6-10芳基氧基)羰基,优选三乙基硅基、三异丙基硅基、叔丁基二甲基硅基、叔丁基二苯基硅基、甲基、叔丁基、烯丙基、苄基、甲氧基甲基、乙氧基乙基、2-四氢吡喃基、甲酰基、乙酰基、苯甲酰基。
  3. 根据权利要求1所述的制备方法,其中R 4、R 4’各自独立地选自氢原子或任选被卤素、羟基、氨基、氧基、羧基、硝基、氰基、C 2-C 6烯基、C 2-C 6炔基、C 1-C 6烷氧基中的一个或多个取代基所取代的以下基团:C 1-C 6烷基、羧基、C 1-C 6烷氧基、磺酰基、C 2-C 6烯基、3至12元环烷基、苯基、萘基、吡咯烷基、咪唑烷基、四氢呋喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、吗啉基、硫代吗啉基、高哌嗪基、咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基;或R 4、R 4’与N原子形成任选被卤素、羟基、氨基、氧基、羧基、硝基、氰基、C 2-C 6烯基、C 2-C 6炔基、C 1-C 6烷氧基中的一个或多个取代基所取代的五元或六元杂环基、杂芳基。
  4. 根据权利要求1所述的制备方法,其中B是被选自以下组中的至少一个基团取代的苯基:F、Cl和甲氧基。
  5. 根据权利要求1所述的制备方法,其中Y任选被以下基团中的一种或多种取代:(C 1-10烷基或芳香基)酰基、(C 1-6烷基或C 6-10芳基)磺酰基、(C 1-6烷氧基或C 6-10芳基氧基)羰基、卤素、CN、CH 3-O-、-C(O)CH=CH 2、-C(O)CH=CHCH 2N(CH 3) 2、-NHC(O)CH=CH 2、-NHC(O)CH=CHCH 2N(CH 3) 2
    -C(O)CH=CHCH 2N(CH 3)(COOC(CH 3) 3;-C(O)CH=CHCH 2NH(CH 3)、-C(O)CH 2CH 3
    -C(O)CH 2CH 2CH 3
    Figure PCTCN2020118309-appb-100003
    -C(O)CH 2CN、
    Figure PCTCN2020118309-appb-100004
    Figure PCTCN2020118309-appb-100005
  6. 根据权利要求1所述的制备方法,其中Y选自任选被取代的以下基团:哌啶基、苯基、二环[3.2.1]辛烷基、氮杂环丁烷基和吡咯烷基。
  7. 根据权利要求1所述的制备方法,其中所述氧化剂选自醌类氧化剂、酸性介质氧化剂、碱性介质氧化剂、中性氧化剂,优选醌类氧化剂,更优选DDQ。
  8. 根据权利要求1所述的制备方法,其中所述式II所示化合物与氧化剂的摩尔比为2:1~1:20,优选1:1~1:8。
  9. 根据权利要求1所述的制备方法,其中所述式II所示化合物选自式IIb所示化合物,
    Figure PCTCN2020118309-appb-100006
    其中,R 1、R 2、R a、A、m的定义如权利要求1所述,R 5选自氢原子、(C 1-10烷基或芳香基)酰基、(C 1-6烷基或C 6-10芳基)磺酰基、(C 1-6烷氧基或C 6-10芳基氧基)羰基、
    卤素、CN、CH 3-O-、-C(O)CH=CH 2、-C(O)CH=CHCH 2N(CH 3) 2、-NHC(O)CH=CH 2、-NHC(O)CH=CHCH 2N(CH 3) 2
    -C(O)CH=CHCH 2N(CH 3)(COOC(CH 3) 3;-C(O)CH=CHCH 2NH(CH 3)、-C(O)CH 2CH 3
    -C(O)CH 2CH 2CH 3
    Figure PCTCN2020118309-appb-100007
    -C(O)CH 2CN、
    Figure PCTCN2020118309-appb-100008
    Figure PCTCN2020118309-appb-100009
    R c各自独立地选自氢原子、卤素、羟基、硝基、氰基、羧基、氨基、C 1-C 6烷基、卤代C 1-C 6烷基、卤代C 1-C 6烷氧基或C 1-C 6烷氧基;
    n为0、1、2、3、4或5,p为1或2。
  10. 根据权利要求9所述的制备方法,其中所述式II所示化合物选自式IIc所示化合物,所述式III所示化合物选自式IIIc所示化合物,
    Figure PCTCN2020118309-appb-100010
    其中,R 1、R 5、R c、p、n的定义如权利要求9所述,R 3如的定义权利要求1所述。
  11. 一种制备式VIIc所示化合物的制备方法,包括如权利要求10所述的制备式IIIc所示化合物的步骤,
    Figure PCTCN2020118309-appb-100011
    其中,R 5、R c、p、n的定义如权利要求10所述。
  12. 根据权利要求11所述的制备方法,其中所述制备方法还包括式IIIc所示化合物制备式IVc所示化合物的步骤,
    Figure PCTCN2020118309-appb-100012
    其中,R 5、R c、p、n的定义如权利要求10所述,R 3如的定义权利要求1所述。
  13. 根据权利要求12所述的制备方法,其中所述制备方法还包括式IVc所示化合物制备式Vc所示化合物的步骤,
    Figure PCTCN2020118309-appb-100013
    其中,R 5、R c、p、n的定义如权利要求10所述,R 3如的定义权利要求1所述。
  14. 根据权利要求13所述的制备方法,其中所述制备方法还包括式Vc所示化合物制备式VIc所示化合物的步骤,
    Figure PCTCN2020118309-appb-100014
    其中,R 6选自C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基羰基、C 1-C 6烷基氨基羰基、C 1-C 6烷基磺酰基、3至12元环烷基、3至12元杂环基、6至14元芳基或5至12元杂芳基,优选C 1-C 6烷基,更优选乙基,
    其中,R 5、R c、p、n的定义如权利要求10所述。
  15. 根据权利要求12所述的制备方法,其中所述制备方法还包括式IVc所示化合物制备式Vc’所示化合物的步骤,
    Figure PCTCN2020118309-appb-100015
    其中,R 6选自C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基羰基、C 1-C 6烷基氨基羰基、C 1-C 6烷基磺酰基、3至12元环烷基、3至12元杂环基、6至14元芳基或5至12元杂芳基,优选C 1-C 6烷基,更优选乙基,
    其中,R 5、R c、p、n的定义如权利要求10所述,R 3如的定义权利要求1所述。
  16. 根据权利要求15所述的制备方法,其中所述制备方法还包括式Vc’所示化合物制备式VIc所示化合物的步骤,
    Figure PCTCN2020118309-appb-100016
    其中,R 5、R c、p、n的定义如权利要求10所述,R 3如的定义权利要求1所述,R 6如的定义权利要求15所述。
  17. 根据权利要求14或16所述的制备方法,其中所述制备方法还包括式VIc所示化合物制备式VIIc所示化合物的步骤,
    Figure PCTCN2020118309-appb-100017
    其中,R 5、R c、p、n的定义如权利要求10所述,R 6选自C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基羰基、C 1-C 6烷基氨基羰基、C 1-C 6烷基磺酰基、3至12元环烷基、3至12元杂环基、6至14元芳基或5至12元杂芳基,优选C 1-C 6烷基,更优选乙基。
  18. 一种式I所示化合物或其可药用盐的制备方法,包括权利要求11-17任意一项所述的制备式VIIc所示化合物的步骤,
    Figure PCTCN2020118309-appb-100018
    其中,式VIIc所示化合物选自式VIIc’所示化合物,R 5选自氨基保护基。
  19. 根据权利要求18所述的制备方法,其中所述制备方法还包括式VIIc’所示化合物制备式VIIIc’所示化合物的步骤,
    Figure PCTCN2020118309-appb-100019
  20. 根据权利要求19所述的制备方法,其中所述制备方法还包括式VIIIc’所示化合物制备式I所示化合物的步骤,
    Figure PCTCN2020118309-appb-100020
  21. 一种式I所示化合物或其可药用盐的制备方法,包括
    Figure PCTCN2020118309-appb-100021
  22. 根据权利要求21所述的制备方法,其中所述制备方法还包括
    Figure PCTCN2020118309-appb-100022
PCT/CN2020/118309 2019-09-29 2020-09-28 一种吡咯并氨基哒嗪酮化合物的制备方法 WO2021057998A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910932516 2019-09-29
CN201910932516.2 2019-09-29

Publications (1)

Publication Number Publication Date
WO2021057998A1 true WO2021057998A1 (zh) 2021-04-01

Family

ID=75165598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/118309 WO2021057998A1 (zh) 2019-09-29 2020-09-28 一种吡咯并氨基哒嗪酮化合物的制备方法

Country Status (2)

Country Link
TW (1) TW202126640A (zh)
WO (1) WO2021057998A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112745255A (zh) * 2019-10-30 2021-05-04 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的制备方法
CN114989062A (zh) * 2022-07-04 2022-09-02 上海再启生物技术有限公司 一种btk激酶抑制剂中间体的晶型及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282725A (zh) * 2005-08-10 2008-10-08 武田药品工业株式会社 糖尿病治疗剂
WO2010046780A2 (en) * 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
CN102648183A (zh) * 2009-10-07 2012-08-22 卡罗生物股份公司 作为雌激素受体配体的取代吡唑
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
CN105837576A (zh) * 2015-01-14 2016-08-10 湖北生物医药产业技术研究院有限公司 Btk抑制剂
WO2018017633A1 (en) * 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN108463460A (zh) * 2016-01-08 2018-08-28 先正达参股股份有限公司 杀微生物的噁二唑衍生物
WO2019196915A1 (zh) * 2018-04-13 2019-10-17 江苏恒瑞医药股份有限公司 一种吡咯并氨基哒嗪酮化合物的制备方法及其中间体

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282725A (zh) * 2005-08-10 2008-10-08 武田药品工业株式会社 糖尿病治疗剂
WO2010046780A2 (en) * 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
CN102648183A (zh) * 2009-10-07 2012-08-22 卡罗生物股份公司 作为雌激素受体配体的取代吡唑
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
CN106573001A (zh) * 2014-07-07 2017-04-19 永恒生物科技公司 作为蛋白激酶抑制剂的氨基哒嗪酮化合物
CN105837576A (zh) * 2015-01-14 2016-08-10 湖北生物医药产业技术研究院有限公司 Btk抑制剂
CN108463460A (zh) * 2016-01-08 2018-08-28 先正达参股股份有限公司 杀微生物的噁二唑衍生物
WO2018017633A1 (en) * 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
WO2019196915A1 (zh) * 2018-04-13 2019-10-17 江苏恒瑞医药股份有限公司 一种吡咯并氨基哒嗪酮化合物的制备方法及其中间体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DADIBOYENA, S. ; VALENTE, E.J. ; HAMME, A.T.: "Synthesis of novel pyrazoles via [2+3]-dipolar cycloaddition using alkyne surrogates", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM , NL, vol. 51, no. 9, 3 March 2010 (2010-03-03), Amsterdam , NL, pages 1341 - 1343, XP026874168, ISSN: 0040-4039 *
LI FU-RONG, ZHANG YU-JUAN, GUO FENG-GUANG, DUAN GUI-YUN, GE YAN-QING: "3-(4-Bromophenyl)-1-(4-chlorobenzyl)-1 H -pyrazole-5-carbaldehyde", ACTA CRYSTALLOGRAPHICA SECTION E STRUCTURE REPORTS ONLINE, vol. 68, no. 7, 15 July 2012 (2012-07-15), pages o2203 - o2203, XP055794410, DOI: 10.1107/S1600536812027298 *
LI QINGJIANG, JIANG JINGQIAN, FAN AILI, CUI YUXIN, JIA YANXING: "Total Synthesis of Lamellarins D, H, and R and Ningalin B", ORGANIC LETTERS ., AMERICAN CHEMICAL SOCIETY, US, vol. 13, no. 2, 21 January 2011 (2011-01-21), US, pages 312 - 315, XP055794415, ISSN: 1523-7060, DOI: 10.1021/ol1027877 *
NAYAK MALOY, BATRA SANJAY: "Synthesis of substituted pyrazolo[4,3-b]pyridines via copper-mediated intramolecular C–N cross-coupling of primary allylamines", RSC ADVANCES, vol. 2, no. 8, 1 January 2012 (2012-01-01), pages 3367, XP055794417, DOI: 10.1039/c2ra01170k *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112745255A (zh) * 2019-10-30 2021-05-04 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的制备方法
CN114989062A (zh) * 2022-07-04 2022-09-02 上海再启生物技术有限公司 一种btk激酶抑制剂中间体的晶型及其制备方法

Also Published As

Publication number Publication date
TW202126640A (zh) 2021-07-16

Similar Documents

Publication Publication Date Title
CN109678796B (zh) Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CA2883545C (en) Imidazoline derivatives, preparation methods thereof, and their applications in medicine
CN102448961B (zh) 作为用于治疗生育力病症的fsh受体激动剂的(二氢)咪唑并异[5,1-a]喹啉
WO2021057998A1 (zh) 一种吡咯并氨基哒嗪酮化合物的制备方法
CN111094279B (zh) 一种苯并呋喃衍生物的制备方法
WO2007121390A1 (en) Process for making cytokine inhibiting compounds containing 4- and 5- imidazolyl rings and the intermediates thereof
CN102036983A (zh) 制备5-(2-氨基-嘧啶-4-基)-2-芳基-1h-吡咯-3-甲酰胺的方法
WO2019196915A1 (zh) 一种吡咯并氨基哒嗪酮化合物的制备方法及其中间体
TWI623521B (zh) 一種製備利馬前列素的中間體、其製備方法以及藉由其製備利馬前列素的方法
CN112341377A (zh) 一种杂环类化合物及其应用
TW202019904A (zh) 一種凝血因子XIa抑制劑及其中間體的製備方法
JPWO2017164379A1 (ja) 2−アルキルカルボニルナフト[2,3−b]フラン−4,9−ジオンの関連物質の製造方法、及びその関連物質
US20050245750A1 (en) Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative
WO2014094511A1 (zh) 一种制备曲前列尼尔的中间体、其制备方法以及通过其制备曲前列尼尔的方法
Gein et al. Synthesis and Structure of 5-Aryl-4-[hydroxy (phenyl) methylene]-1-[2-(1 H-indol-3-yl) ethyl] pyrrolidine-2, 3-diones
CN108017522B (zh) 一种2,6-二溴苯甲磺酰氯的制备工艺
CN111848625B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类化合物的制备方法及中间体
JP7063487B2 (ja) ピラン縮合環系化合物、その製造方法及び使用
CN117355513A (zh) 一种btk抑制剂中间体的制备方法
WO2018099424A1 (zh) 一种吡啶酮类衍生物的制备方法及其中间体
JP7429236B2 (ja) ホステムサビルの調製方法
RU2777597C2 (ru) Способ получения ингибитора parp и его промежуточного соединения
CN111718295B (zh) 一种高纯度米力农的制备方法
EP1874777A1 (fr) Dérivés de 1 h-pyrimido[4,5-b]indole, leur préparation et leur application en thérapeutique
WO2021184609A1 (zh) 一种米力农中间体的制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20868706

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20868706

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20868706

Country of ref document: EP

Kind code of ref document: A1